FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4232514955> ?p ?o ?g. }

• W4232514955 endingPage "404" @default.
• W4232514955 startingPage "394" @default.
• W4232514955 abstract "We (JMAAV [Japanese patients with MPO-ANCA-associated vasculitis] Study Group) performed a prospective, open-label, multi-center trial to evaluate the usefulness of severity-based treatment in Japanese patients with myeloperoxidase-anti-neutrophil cytoplasmic antibodies (MPO-ANCA)-associated vasculitis. Patients with MPO-ANCA-associated vasculitis received a severity-based regimen according to the appropriate protocol: low-dose corticosteroid and, if necessary, cyclophosphamide or azathioprine in patients with mild form; high-dose corticosteroid and cyclophosphamide in those with severe form; and the severe-form regimen plus plasmapheresis in those with the most severe form. We followed up the patients for 18 months. The primary end points were the induction of remission, death, and end-stage renal disease (ESRD). Fifty-two patients were registered, and 48 patients were enrolled in this study (mild form, n = 23; severe form, n = 23; most severe form, n = 2). Among the 47 patients who received the predefined therapies, 42 achieved remission within 6 months, 5 died, and 1 developed ESRD. Disease flared up in 8 of the 42 patients with remission during the 18-month follow-up period. The JMAAV trial is the first prospective trial for MPO-ANCA-associated vasculitis to be performed in Japan. The remission and death rates were comparable to those in several previous clinical trials performed in western counties. The regimen employed in this trial was tailor-made based on patients’ disease severity and disease type, and it seems that standardization can be consistent with treatment choices made according to severity." @default.
• W4232514955 created "2022-05-12" @default.
• W4232514955 creator A5004286098 @default.
• W4232514955 creator A5004411250 @default.
• W4232514955 creator A5016250705 @default.
• W4232514955 creator A5024647021 @default.
• W4232514955 creator A5032051871 @default.
• W4232514955 creator A5036962794 @default.
• W4232514955 creator A5039655833 @default.
• W4232514955 creator A5042371014 @default.
• W4232514955 creator A5053032425 @default.
• W4232514955 creator A5066568101 @default.
• W4232514955 creator A5073572164 @default.
• W4232514955 creator A5077118284 @default.
• W4232514955 creator A5077453014 @default.
• W4232514955 creator A5078494019 @default.
• W4232514955 creator A5079071350 @default.
• W4232514955 creator A5079821787 @default.
• W4232514955 creator A5082674163 @default.
• W4232514955 creator A5087300715 @default.
• W4232514955 date "2012-06-01" @default.
• W4232514955 modified "2023-10-03" @default.
• W4232514955 title "Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study" @default.
• W4232514955 cites W1979398789 @default.
• W4232514955 cites W1981535363 @default.
• W4232514955 cites W2011309580 @default.
• W4232514955 cites W2036292718 @default.
• W4232514955 cites W2039582264 @default.
• W4232514955 cites W2065537803 @default.
• W4232514955 cites W2071333258 @default.
• W4232514955 cites W2080674117 @default.
• W4232514955 cites W2094390378 @default.
• W4232514955 cites W2099012616 @default.
• W4232514955 cites W2126960177 @default.
• W4232514955 cites W2132795660 @default.
• W4232514955 cites W2162725007 @default.
• W4232514955 cites W4234522638 @default.
• W4232514955 doi "https://doi.org/10.3109/s10165-011-0525-5" @default.
• W4232514955 hasPublicationYear "2012" @default.
• W4232514955 type Work @default.
• W4232514955 citedByCount "52" @default.
• W4232514955 countsByYear W42325149552013 @default.
• W4232514955 countsByYear W42325149552014 @default.
• W4232514955 countsByYear W42325149552015 @default.
• W4232514955 countsByYear W42325149552016 @default.
• W4232514955 countsByYear W42325149552017 @default.
• W4232514955 countsByYear W42325149552018 @default.
• W4232514955 countsByYear W42325149552019 @default.
• W4232514955 countsByYear W42325149552020 @default.
• W4232514955 countsByYear W42325149552021 @default.
• W4232514955 countsByYear W42325149552022 @default.
• W4232514955 countsByYear W42325149552023 @default.
• W4232514955 crossrefType "journal-article" @default.
• W4232514955 hasAuthorship W4232514955A5004286098 @default.
• W4232514955 hasAuthorship W4232514955A5004411250 @default.
• W4232514955 hasAuthorship W4232514955A5016250705 @default.
• W4232514955 hasAuthorship W4232514955A5024647021 @default.
• W4232514955 hasAuthorship W4232514955A5032051871 @default.
• W4232514955 hasAuthorship W4232514955A5036962794 @default.
• W4232514955 hasAuthorship W4232514955A5039655833 @default.
• W4232514955 hasAuthorship W4232514955A5042371014 @default.
• W4232514955 hasAuthorship W4232514955A5053032425 @default.
• W4232514955 hasAuthorship W4232514955A5066568101 @default.
• W4232514955 hasAuthorship W4232514955A5073572164 @default.
• W4232514955 hasAuthorship W4232514955A5077118284 @default.
• W4232514955 hasAuthorship W4232514955A5077453014 @default.
• W4232514955 hasAuthorship W4232514955A5078494019 @default.
• W4232514955 hasAuthorship W4232514955A5079071350 @default.
• W4232514955 hasAuthorship W4232514955A5079821787 @default.
• W4232514955 hasAuthorship W4232514955A5082674163 @default.
• W4232514955 hasAuthorship W4232514955A5087300715 @default.
• W4232514955 hasBestOaLocation W42325149551 @default.
• W4232514955 hasConcept C126322002 @default.
• W4232514955 hasConcept C141071460 @default.
• W4232514955 hasConcept C188816634 @default.
• W4232514955 hasConcept C24040308 @default.
• W4232514955 hasConcept C2776015282 @default.
• W4232514955 hasConcept C2776694085 @default.
• W4232514955 hasConcept C2776755627 @default.
• W4232514955 hasConcept C2776760755 @default.
• W4232514955 hasConcept C2777374719 @default.
• W4232514955 hasConcept C2778910314 @default.
• W4232514955 hasConcept C2779134260 @default.
• W4232514955 hasConcept C2781413609 @default.
• W4232514955 hasConcept C71924100 @default.
• W4232514955 hasConcept C90924648 @default.
• W4232514955 hasConceptScore W4232514955C126322002 @default.
• W4232514955 hasConceptScore W4232514955C141071460 @default.
• W4232514955 hasConceptScore W4232514955C188816634 @default.
• W4232514955 hasConceptScore W4232514955C24040308 @default.
• W4232514955 hasConceptScore W4232514955C2776015282 @default.
• W4232514955 hasConceptScore W4232514955C2776694085 @default.
• W4232514955 hasConceptScore W4232514955C2776755627 @default.
• W4232514955 hasConceptScore W4232514955C2776760755 @default.
• W4232514955 hasConceptScore W4232514955C2777374719 @default.
• W4232514955 hasConceptScore W4232514955C2778910314 @default.
• W4232514955 hasConceptScore W4232514955C2779134260 @default.
• W4232514955 hasConceptScore W4232514955C2781413609 @default.

• next